AGIOS PHARMACEUTICALS, INC. (AGIO) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
43/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseAGIO / S&P 9.70% / 15.20% |
WinAGIO / S&P 140.58% / 15.00% |
LoseAGIO / S&P -163.73% / 50.40% |
| 2026-Q12/3 |
WinAGIO / S&P 24.28% / -4.33% |
WinAGIO / S&P 78.34% / 11.30% |
LoseAGIO / S&P -164.50% / 27.70% |
| 2025-Q41/3 |
LoseAGIO / S&P -32.19% / 2.65% |
WinAGIO / S&P 48.03% / 9.00% |
LoseAGIO / S&P -162.70% / 13.40% |
| 2025-Q32/3 |
WinAGIO / S&P 20.69% / 8.12% |
WinAGIO / S&P 36.26% / 4.61% |
LoseAGIO / S&P -161.62% / 13.45% |
| 2025-Q22/3 |
WinAGIO / S&P 13.52% / 10.94% |
WinAGIO / S&P 30.57% / 4.83% |
LoseAGIO / S&P -269.23% / 10.63% |
| 2025-Q11/3 |
LoseAGIO / S&P -10.83% / -4.27% |
WinAGIO / S&P 25.96% / 4.98% |
LoseAGIO / S&P -277.85% / 10.57% |
| 2024-Q41/3 |
LoseAGIO / S&P -26.04% / 2.41% |
WinAGIO / S&P 36.07% / 5.25% |
LoseAGIO / S&P -278.86% / 6.15% |
| 2024-Q31/3 |
LoseAGIO / S&P 3.04% / 5.89% |
WinAGIO / S&P 36.79% / 5.89% |
LoseAGIO / S&P -387.59% / 6.11% |
| 2024-Q23/3 |
WinAGIO / S&P 47.47% / 4.28% |
WinAGIO / S&P 55.39% / 5.38% |
WinAGIO / S&P 71.05% / 5.12% |
| 2024-Q13/3 |
WinAGIO / S&P 31.30% / 10.56% |
WinAGIO / S&P 54.61% / 5.71% |
WinAGIO / S&P 59.19% / 5.59% |
| 2023-Q42/3 |
LoseAGIO / S&P -10.02% / 11.69% |
WinAGIO / S&P 88.36% / 6.81% |
WinAGIO / S&P 49.53% / 7.78% |
| 2023-Q31/3 |
LoseAGIO / S&P -12.61% / -3.27% |
WinAGIO / S&P 141.99% / 7.52% |
LoseAGIO / S&P -28.83% / -5.03% |
| 2023-Q22/3 |
WinAGIO / S&P 23.29% / 8.74% |
WinAGIO / S&P 214.11% / 9.50% |
LoseAGIO / S&P -32.38% / -8.57% |
| 2023-Q11/3 |
LoseAGIO / S&P -18.20% / 7.50% |
WinAGIO / S&P 2185.70% / 10.77% |
LoseAGIO / S&P -25.79% / -15.69% |
| 2022-Q40/3 |
LoseAGIO / S&P -0.71% / 7.56% |
LoseAGIO / S&P AGIO unavailable / 11.88% |
LoseAGIO / S&P -118.17% / -17.99% |
| 2022-Q31/3 |
WinAGIO / S&P 27.56% / -4.88% |
LoseAGIO / S&P -106.24% / 13.47% |
LoseAGIO / S&P -124.59% / -1.41% |
| 2022-Q20/3 |
LoseAGIO / S&P -23.84% / -16.10% |
LoseAGIO / S&P -105.15% / 13.71% |
LoseAGIO / S&P -124.76% / 11.04% |
| 2022-Q10/3 |
LoseAGIO / S&P -11.44% / -4.60% |
LoseAGIO / S&P -100.96% / 15.97% |
LoseAGIO / S&P -123.46% / 42.23% |
| 2021-Q40/3 |
LoseAGIO / S&P -28.78% / 11.03% |
LoseAGIO / S&P AGIO unavailable / 15.00% |
LoseAGIO / S&P -592.41% / 96.40% |
| 2021-Q30/3 |
LoseAGIO / S&P -16.26% / 0.58% |
LoseAGIO / S&P -181.79% / 10.77% |
LoseAGIO / S&P AGIO unavailable / 69.42% |
| 2021-Q20/3 |
LoseAGIO / S&P 6.72% / 8.55% |
LoseAGIO / S&P -166.94% / 6.58% |
LoseAGIO / S&P AGIO unavailable / 51.81% |
| 2021-Q11/3 |
WinAGIO / S&P 19.18% / 6.17% |
LoseAGIO / S&P -149.83% / -1.06% |
LoseAGIO / S&P AGIO unavailable / 7.39% |
| 2020-Q41/3 |
WinAGIO / S&P 23.80% / 12.15% |
LoseAGIO / S&P -100.00% / -3.72% |
LoseAGIO / S&P AGIO unavailable / -33.42% |
| 2020-Q31/3 |
LoseAGIO / S&P -34.55% / 8.93% |
WinAGIO / S&P 72.99% / -2.04% |
LoseAGIO / S&P AGIO unavailable / -27.10% |
| 2020-Q22/3 |
WinAGIO / S&P 50.73% / 20.54% |
WinAGIO / S&P 82.88% / -0.46% |
LoseAGIO / S&P AGIO unavailable / -27.11% |
| 2020-Q11/3 |
LoseAGIO / S&P -25.70% / -19.60% |
WinAGIO / S&P 50.87% / 3.47% |
LoseAGIO / S&P AGIO unavailable / -14.75% |
| 2019-Q42/3 |
WinAGIO / S&P 47.38% / 9.07% |
WinAGIO / S&P 24.92% / 5.36% |
LoseAGIO / S&P AGIO unavailable / 2.99% |
| 2019-Q31/3 |
LoseAGIO / S&P -35.04% / 1.70% |
WinAGIO / S&P 51.65% / 5.02% |
LoseAGIO / S&P AGIO unavailable / 0.21% |
| 2019-Q21/3 |
LoseAGIO / S&P -26.04% / 4.30% |
WinAGIO / S&P 44.54% / 6.64% |
LoseAGIO / S&P AGIO unavailable / 8.65% |
| 2019-Q12/3 |
WinAGIO / S&P 46.26% / 13.65% |
WinAGIO / S&P 180.75% / 8.12% |
LoseAGIO / S&P AGIO unavailable / 14.29% |
| 2018-Q41/3 |
LoseAGIO / S&P -40.21% / -13.52% |
WinAGIO / S&P 119.45% / 9.05% |
LoseAGIO / S&P AGIO unavailable / 18.23% |
| 2018-Q31/3 |
LoseAGIO / S&P -8.44% / 7.71% |
WinAGIO / S&P 32.78% / 10.21% |
LoseAGIO / S&P AGIO unavailable / 19.06% |
| 2018-Q21/3 |
LoseAGIO / S&P 3.00% / 3.43% |
WinAGIO / S&P 31.50% / 9.03% |
LoseAGIO / S&P AGIO unavailable / 14.46% |
| 2018-Q11/3 |
WinAGIO / S&P 43.05% / -0.76% |
LoseAGIO / S&P -15.99% / 7.68% |
LoseAGIO / S&P AGIO unavailable / 12.46% |
| 2017-Q40/3 |
LoseAGIO / S&P -14.35% / 6.64% |
LoseAGIO / S&P AGIO unavailable / 7.03% |
LoseAGIO / S&P AGIO unavailable / 13.82% |
| 2017-Q31/3 |
WinAGIO / S&P 29.74% / 4.48% |
LoseAGIO / S&P AGIO unavailable / 5.68% |
LoseAGIO / S&P AGIO unavailable / 17.57% |
| 2017-Q20/3 |
LoseAGIO / S&P -11.90% / 3.09% |
LoseAGIO / S&P AGIO unavailable / 4.83% |
LoseAGIO / S&P AGIO unavailable / 17.74% |
| 2017-Q11/3 |
WinAGIO / S&P 39.95% / 6.07% |
LoseAGIO / S&P AGIO unavailable / 3.67% |
LoseAGIO / S&P AGIO unavailable / 13.32% |
| 2016-Q40/3 |
LoseAGIO / S&P -21.00% / 3.82% |
LoseAGIO / S&P AGIO unavailable / 2.09% |
LoseAGIO / S&P AGIO unavailable / 7.05% |
| 2016-Q31/3 |
WinAGIO / S&P 26.06% / 3.85% |
LoseAGIO / S&P AGIO unavailable / 0.20% |
LoseAGIO / S&P AGIO unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | AGIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -9.10% | 20.78% |
| Annualized return | -9.10% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | AGIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -25.15% | 83.14% |
| Annualized return | -5.63% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | AGIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -6.70% | 319.30% |
| Annualized return | -0.69% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |